{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:28:38Z","timestamp":1781270918269,"version":"3.54.1"},"reference-count":44,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,10,18]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Patients with psoriatic arthritis (PsA) are at a significantly increased risk of hyperuricaemia and development of gout, and those with hyperuricaemia have been found to respond poorly to PsA treatment and have more peripheral and destructive joint damage. We present a comprehensive post hoc analysis using pooled data from the FUTURE 2\u20135 studies and the MAXIMISE study to further evaluate the impact of hyperuricaemia on clinical presentation\/disease severity and response to secukinumab in patients with PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients were stratified into two groups based on baseline serum uric acid (SUA) level (threshold of 360\u2009\u00b5mol\/L). A sensitivity analysis was also performed based on SUA thresholds of 300\u2009\u00b5mol\/L and 420\u2009\u00b5mol\/L. Demographics, clinical, radiological characteristics and comorbidities data were collected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At baseline, patients with hyperuricaemia were mostly male, reported a higher prevalence of hypertension, with more clinical dactylitis, more psoriasis and more severe skin disease compared with patients with normouricaemia. A similar proportion of patients in the normouricaemic and hyperuricaemic cohorts achieved American College of Rheumatology responses, resolution of enthesitis and dactylitis, inhibition of structural damage progression and improvement in health-related quality of life across all secukinumab doses at week 52.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients with PsA and hyperuricaemia have different clinical characteristics from patients with PsA and normouricaemia. Identification of these patients at an early stage may facilitate a personalised treatment approach and improved management of comorbidities. Furthermore, secukinumab provided a rapid and sustained response across all manifestations of PsA up to week 52, irrespective of baseline uricaemia status.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003428","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T10:26:57Z","timestamp":1699525617000},"page":"e003428","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2\u20135 and MAXIMISE studies"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-4032","authenticated-orcid":false,"given":"Renaud","family":"Felten","sequence":"first","affiliation":[{"name":"Department of Rheumatology, National Reference Centre for Rare East-South-West Autoimmune Systemic Diseases (RESO), Strasbourg University Hospitals, Strasbourg, Grand Est, France"},{"name":"UPR 3572, Laboratory of Immunopathology and Therapeutic Chemistry, Institute of Molecular and Cellular Biology, Strasbourg, Alsace, France"},{"name":"Center of Clinical Investigation, Inserm 1434, Strasbourg University Hospitals, Strasbourg, Grand Est, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Widawski","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Civilian Hospitals Colmar, Colmar, Alsace, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Spielmann","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Civilian Hospitals Colmar, Colmar, Alsace, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine","family":"Gaillez","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Basel-Stadt, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Bao","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9469-946X","authenticated-orcid":false,"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, National Reference Centre for Rare East-South-West Autoimmune Systemic Diseases (RESO), Strasbourg University Hospitals, Strasbourg, Grand Est, France"},{"name":"UPR 3572, Laboratory of Immunopathology and Therapeutic Chemistry, Institute of Molecular and Cellular Biology, Strasbourg, Alsace, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Marie","family":"Duret","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Civilian Hospitals Colmar, Colmar, Alsace, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Messer","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Civilian Hospitals Colmar, Colmar, Alsace, France"},{"name":"UMR 7367, Dynamiques Europ\u00e9ennes, Strasbourg, Grand Est, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"2025090312134334000_9.4.e003428.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30830-4"},{"key":"2025090312134334000_9.4.e003428.2","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.737573","article-title":"Hyperuricemia in psoriatic arthritis: epidemiology, pathophysiology, and clinical implications","volume":"8","author":"Tripolino","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025090312134334000_9.4.e003428.3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40744-019-0159-1","article-title":"Psoriatic arthritis: what is happening at the joint?","volume":"6","author":"Belasco","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2025090312134334000_9.4.e003428.4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of life in psoriatic arthritis","volume":"14","author":"Gudu","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2025090312134334000_9.4.e003428.5","doi-asserted-by":"crossref","first-page":"108397","DOI":"10.1016\/j.clim.2020.108397","article-title":"Comorbidities associated with psoriatic arthritis: review and update","volume":"214","author":"Perez-Chada","year":"2020","journal-title":"Clin Immunol"},{"key":"2025090312134334000_9.4.e003428.6","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10067-020-04981-0","article-title":"At the crossroads of gout and psoriatic arthritis: \"Psout\"","volume":"39","author":"Felten","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2025090312134334000_9.4.e003428.7","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1051\/medsci\/2021118","article-title":"Quelle Taxonomie des maladies Inflammatoires en Rhumatologie? - le concept de Psoutte","volume":"37","author":"Messer","year":"2021","journal-title":"Med Sci (Paris)"},{"key":"2025090312134334000_9.4.e003428.8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","article-title":"Gout","volume":"5","author":"Dalbeth","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2025090312134334000_9.4.e003428.9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170384"},{"key":"2025090312134334000_9.4.e003428.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.005"},{"key":"2025090312134334000_9.4.e003428.11","doi-asserted-by":"publisher","DOI":"10.1097\/00124743-200002000-00001"},{"key":"2025090312134334000_9.4.e003428.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2010.03988.x"},{"key":"2025090312134334000_9.4.e003428.13","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/1756-185X.13265","article-title":"Hyperuricemia in Asian psoriatic arthritis patients","volume":"21","author":"Lai","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"2025090312134334000_9.4.e003428.14","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.645550","article-title":"Updated evidence of the association between elevated serum uric acid level and psoriasis","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025090312134334000_9.4.e003428.15","doi-asserted-by":"publisher","DOI":"10.1038\/nature04516"},{"key":"2025090312134334000_9.4.e003428.16","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/1346-8138.13968","article-title":"Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients","volume":"44","author":"Tsuruta","year":"2017","journal-title":"J Dermatol"},{"key":"2025090312134334000_9.4.e003428.17","doi-asserted-by":"publisher","DOI":"10.1097\/00000372-198100340-00014"},{"key":"2025090312134334000_9.4.e003428.18","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s10753-018-0839-y","article-title":"Changes of Treg\/Th17 ratio in spleen of acute gouty arthritis rat induced by MSU crystals","volume":"41","author":"Dai","year":"2018","journal-title":"Inflammation"},{"key":"2025090312134334000_9.4.e003428.19","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3"},{"key":"2025090312134334000_9.4.e003428.20","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jhep.2015.11.022","article-title":"Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 Inflammasome-dependent mechanism","volume":"64","author":"Wan","year":"2016","journal-title":"J Hepatol"},{"key":"2025090312134334000_9.4.e003428.21","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12051260","article-title":"Assessment of crystals in the synovial fluid of psoriatic arthritis patients in relation to disease activity","volume":"12","author":"Geneva-Popova","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"2025090312134334000_9.4.e003428.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2012.08.006"},{"key":"2025090312134334000_9.4.e003428.23","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1177\/15353702221110666","article-title":"\u201cAcute joint swelling in psoriatic arthritis: flare or \"Psout\"-a 10-year-Monocentric study on Synovial fluid\u201d","volume":"247","author":"Galozzi","year":"2022","journal-title":"Exp Biol Med (Maywood)"},{"key":"2025090312134334000_9.4.e003428.24","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10067-022-06061-x","article-title":"Psoriatic arthritis with hyperuricemia: more peripheral, destructive, and challenging to treat","volume":"41","author":"Widawski","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2025090312134334000_9.4.e003428.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"2025090312134334000_9.4.e003428.26","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025090312134334000_9.4.e003428.27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and safety of subcutaneous secukinumab 150mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2025090312134334000_9.4.e003428.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212687"},{"key":"2025090312134334000_9.4.e003428.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218808"},{"key":"2025090312134334000_9.4.e003428.30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/acr2.11097","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of Psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study","volume":"2","author":"Mease","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2025090312134334000_9.4.e003428.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205212"},{"key":"2025090312134334000_9.4.e003428.32","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90441-4"},{"key":"2025090312134334000_9.4.e003428.33","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2147\/DMSO.S232377","article-title":"Converging relationship of obesity and hyperuricemia with special reference to metabolic disorders and plausible therapeutic implications","volume":"13","author":"Gong","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2025090312134334000_9.4.e003428.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(98)90346-8"},{"key":"2025090312134334000_9.4.e003428.35","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32835d951e"},{"key":"2025090312134334000_9.4.e003428.36","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000152"},{"key":"2025090312134334000_9.4.e003428.37","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190114"},{"key":"2025090312134334000_9.4.e003428.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201194"},{"key":"2025090312134334000_9.4.e003428.39","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12742"},{"key":"2025090312134334000_9.4.e003428.40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10067-018-4332-7","article-title":"Role of Comorbidities in Spondyloarthritis including Psoriatic arthritis","volume":"38","author":"Scriffignano","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025090312134334000_9.4.e003428.41","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2009.107755","article-title":"Dactylitis in gout","volume":"69","author":"Andracco","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025090312134334000_9.4.e003428.42","first-page":"1255","article-title":"Association between serum uric acid concentration and clinical features of psoriasis","volume":"34","author":"El Farargy","year":"2021","journal-title":"Menoufia Med J"},{"key":"2025090312134334000_9.4.e003428.43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.6088"},{"key":"2025090312134334000_9.4.e003428.44","first-page":"52","article-title":"GRAPPA treatment recommendations: 2021 update","volume":"49","author":"Coates","year":"2022","journal-title":"J Rheumatol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:13:50Z","timestamp":1756926830000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,11,9]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/rmdopen-2023-003428"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003428","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}